MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Inovio Pharmaceuticals, Inc. (NASDAQ: INO)*
Organization & Developments: Inovio
Parents
Inovio Pharmaceuticals, Inc. (NASDAQ: INO)*
Children
*Its SynCon vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response...
*Leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases
*New generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin
2011: Synthetic vaccine developer, has three drugs in phase 2 clinical trials for cervical cancer, HIV and malaria.(2011)
2016: Did the Market Overreact to Inovio Pharmaceuticals' Clinical Hold?
2016: Expert Opinion: Should Electroporation Spark Greater Investor Interest? - Inovio Pharmaceuticals, Inc. (NYSEMKT:INO)
2016: Inovio Pharmaceuticals (NASDAQ:INO) was up better than five percent on the day as the FDA has approved the start of a Phase I clinical trial to evaluate its Zika DNA vaccine candidate in 40 healthy volunteers.
2018: Inovio Poised For Breakthroughs In 2018 And Beyond - Inovio Pharmaceuticals, Inc. (NYSEMKT:INO)
2018: Inovio's At It Again - Inovio Pharmaceuticals, Inc. (NYSEMKT:INO)
2018: Inovio's China Partnership License Agreement Should Be Cheered - Inovio Pharmaceuticals, Inc. (NYSEMKT:INO)
2019: Inovio Pharmaceuticals Is A Promising Pick In January 2019_seekingalpha.com
2020: If it advances into a larger Ph 2 study, the company expects to have an early vaccine available for emergency use, if approved, by the end of 2020.
2020: Inovio gets $71 million from U.S. defense department for COVID-19 vaccine device
2020: Inovio Pharmaceuticals: Positioning For A Global Opportunity
2020: Inovio Pharmaceuticals: Smart Devices And A Smart Investment
2020: INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine
2020: Inovio: Accumulate For The HPV And Brain Cancer Therapies
2020: Inovio's shares tumble 33% as COVID-19 vaccine trial is put on hold_marketwatch
2020: The company has initiated Ph1 trials in Apr 2020 and expects early results by Aug 2020.
2020: The DoD contract, from the JPEO-CRBND-EB through funding provided by the Defense Health Program, builds upon two separate prior $5 million grants from the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI), to accelerate the testing of CELLECTRA® 3PSP
2020: This Top Covid-19 Play Just Crumbled On Vague Coronavirus Vaccine Data
2021: Inovio VGX-3100 HPV Data Adds To Conviction
2022: Inovio Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2022: Inovio Pharmaceuticals: Catalysts On The Horizon_ seekingalpha.com
2022: Inovio Pharmaceuticals: Long On Promise, Short On Results_seekingalpha.com
2023: Inovio cuts workforce as COVID program weighs down future growth
2023: Inovio says no-go on phase 3 cervical lesion program after clinical setback, lays off 30% of staff_fiercebiotech
2024: Inovio Pharmaceuticals: Takes Another Torpedo But Keeps On Sailing
2024: Inovio Pharmaceuticals: The Dangerous Allure Of A Falling Knife
2024: Inovio Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline progress Investing.com
2024: Inovio: Planning A BLA To Reverse Its Long Path Of Misfortunes
Jumps
*Key People: Inovio
Finance & Acquisitions: Inovio